Recalibrating the anti-corruption, transparency, and accountability formula to advance public health.

Anti-Corruption, Transparency and Accountability Anti-corruption fraud global health risk risk assessment

Journal

Global health action
ISSN: 1654-9880
Titre abrégé: Glob Health Action
Pays: United States
ID NLM: 101496665

Informations de publication

Date de publication:
2020
Historique:
entrez: 21 3 2020
pubmed: 21 3 2020
medline: 1 12 2020
Statut: ppublish

Résumé

Policy-makers, implementing organizations, and funders of global health programs aim to improve health care services and health outcomes through specific projects or systemic change. To mitigate the risk of corruption and its harmful effects on those initiatives, health programs often use multiple anti-corruption mechanisms, including codes of conduct, documentation and reporting requirements, and trainings. Unfortunately, the introduction of anti-corruption mechanisms tends to occur without an explicit consideration of how each mechanism will affect health services and health outcomes. This may overlook potentially more effective approaches. In addition, it may result in the introduction of too many controls (thereby stymying service delivery) and a focus on financial or procurement-related issues (at the expense of service delivery objectives). We argue that anti-corruption efforts in health programs can be more effective if they prioritize addressing issues according to their likelihood and level of harm to key program objectives. Recalibrating the anti-corruption formula in this way will require: (i) extending responsibility and ownership over anti-corruption from subject experts to public health and health system specialists, and (ii) enabling those specialists to apply the Fraud Risk Assessment methodology to develop tailored anti-corruption mechanisms. We fill a documented gap in guidance on how to develop anti-corruption mechanisms by walking through the seven analytical steps of the Fraud Risk Assessment methodology as applicable to health programs. We then outline best practices for any anti-corruption mechanism, including a focus on quality health delivery; the alignment of actors' incentives around the advancement of health objectives; and being minimally corruptible by design.

Identifiants

pubmed: 32194013
doi: 10.1080/16549716.2019.1701327
pmc: PMC7170353
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1701327

Références

Cochrane Database Syst Rev. 2016 Aug 16;(8):CD008856
pubmed: 27528494
BMC Med. 2016 Sep 29;14(1):149
pubmed: 27680102

Auteurs

Aneta Wierzynska (A)

Ethics Office, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Geneva, Switzerland.

Sarah Steingrüber (S)

Independent Global Health Expert, Berlin, Germany.

Roxanne Oroxom (R)

McCourt School of Public Policy, Georgetown University, Washington, DC, USA.

Sebastian Bauhoff (S)

Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA.
Center for Global Development, Washington, DC, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH